Browsing Tag
autosomal dominant hypocalcemia type 1
2 posts
BridgeBio raises $1bn in preferred equity to fund rare disease product launches
BridgeBio’s $1 billion preferred equity raise strengthens BBIO’s balance sheet as Attruby grows and three rare disease launches approach.
How Phase 3 CALIBRATE data reshapes BridgeBio Pharma, Inc.’s rare disease strategy (NASDAQ: BBIO)
Can BridgeBio Pharma, Inc.’s CALIBRATE data turn encaleret into a rare endocrine breakthrough? Explore strategy, risks, and market impact.